Immunocore Holdings plc (IMCR)
NASDAQ: IMCR · Real-Time Price · USD
29.54
+1.14 (4.01%)
At close: May 12, 2025, 4:00 PM
29.54
0.00 (0.00%)
After-hours: May 12, 2025, 4:05 PM EDT
Immunocore Holdings Revenue
Immunocore Holdings had revenue of $93.88M in the quarter ending March 31, 2025, with 33.16% growth. This brings the company's revenue in the last twelve months to $333.58M, up 25.75% year-over-year. In the year 2024, Immunocore Holdings had annual revenue of $310.20M with 24.37% growth.
Revenue (ttm)
$333.58M
Revenue Growth
+25.75%
P/S Ratio
4.43
Revenue / Employee
$676,635
Employees
493
Market Cap
1.48B
Revenue Chart
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2024 | 310.20M | 60.77M | 24.37% |
Dec 31, 2023 | 249.43M | 75.07M | 43.05% |
Dec 31, 2022 | 174.36M | 137.88M | 377.91% |
Dec 31, 2021 | 36.48M | -4.63M | -11.26% |
Dec 31, 2020 | 41.11M | 7.12M | 20.94% |
Dec 31, 2019 | Pro | Pro | Pro |
Dec 31, 2018 | Pro | Pro | Pro |
Dec 31, 2017 | Pro | Pro | Pro |
Dec 31, 2016 | Pro | Pro | Pro |
Dec 31, 2015 | Pro | Pro | Pro |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
UnitedHealth Group | 410.06B |
Johnson & Johnson | 89.33B |
Merck & Co. | 63.92B |
AbbVie | 57.37B |
AstraZeneca | 54.98B |
Novartis AG | 53.22B |
Eli Lilly and Company | 49.00B |
Novo Nordisk | 43.92B |
IMCR News
- 5 days ago - Immunocore reports first quarter financial results and provides a business update - GlobeNewsWire
- 5 weeks ago - Immunocore to present at upcoming investor conferences - GlobeNewsWire
- 2 months ago - Immunocore presents initial multiple ascending dose data for HIV functional cure candidate in an oral presentation at CROI 2025 - GlobeNewsWire
- 2 months ago - Immunocore: A Commercial Biotech Nearing Its Pivotal Break-Even Point - Seeking Alpha
- 2 months ago - Immunocore Holdings plc (IMCR) Q4 2024 Earnings Call Transcript - Seeking Alpha
- 2 months ago - Immunocore reports fourth quarter and full year 2024 financial results and provides a business update - GlobeNewsWire
- 2 months ago - Immunocore to report fourth quarter and full year 2024 financial results and host call on February 26, 2025 - GlobeNewsWire
- 4 months ago - Immunocore announces strategic priorities at 43rd Annual J.P. Morgan Healthcare Conference - GlobeNewsWire